Remission of Bullous Pemphigoid in a Patient Treated with Upadacitinib: A Case Report

Bullous pemphigoid (BP) is a chronic autoimmune blistering disorder that often requires complex medical management. Cases of recalcitrant BP that do not respond to first line agents pose a therapeutic dilemma. Herein, we present a case of recalcitrant BP successfully treated with an oral janus kinase inhibitor, upadacitinib, after limited response with prednisone tapering, doxycycline, dupilumab and omalizumab. We observed substantial improvement following the initiation of upadacitinib after two months, complete remission after six months, and sustained remission one-year post-therapy. This case highlights the emerging potential of JAK inhibitors in managing refractory BP.